Some ovarian cancer patients don't respond well to standard chemo, making it nearly impossible for surgeons to remove the tumors. This project tests a 'booster' strategy by giving chemo more frequently to shrink tumors further. The goal is to turn a hopeless situation into one where surgery is possible and follow-up drugs actually work.
Approximately 35% of ovarian cancer patients are chemo-resistant and cannot undergo complete surgery, leading to a survival rate below 20%. Current high-cost maintenance drugs like PARP inhibitors are ineffective for this specific group.
A pragmatic phase III clinical trial and a numeric diagnostic tool based on CA-125 KELIM scores to identify and treat poor-prognosis patients.
If you are a drug developer dealing with low efficacy of PARP inhibitors in chemo-resistant patients — this project developed a dose-dense chemotherapy regimen that increases the chemosensitivity of 14,000 annual European patients, potentially expanding the effective patient pool for maintenance therapies.
If you are a diagnostics company dealing with imprecise patient stratification — this project developed a numeric tool based on the CA-125 KELIM score to identify the 35% of patients with poor prognosis, allowing for more precise treatment pathways.
If you are a hospital operator dealing with high costs and low survival rates (<20% at 5 years) for refractory ovarian cancer — this project developed a pragmatic clinical trial model to assess the cost-effectiveness of salvage chemotherapy and late debulking surgery.
Based on available project data, specific pricing is not provided, but the project aims to assess the affordability and cost-effectiveness of the strategies including country coverage policies.
The project is designed for scale through a pragmatic phase III trial involving the ENGOT network and approximately 100 recruiting centers across 6 countries.
Based on available project data, the project utilizes the KELIM score; specific licensing terms for the project's implementation of this tool are not mentioned.
The project specifically analyzes the impact of country coverage policies on the prescription of complementary therapeutic strategies.
The project period runs from 2023-05-01 to 2028-04-30.
The consortium consists of 12 partners from 3 countries (BE, ES, FR). It is heavily weighted toward clinical and research entities, with 6 research organizations and 4 other entities, while industry representation is low at 17% (2 partners, including 1 SME). This structure indicates a project focused on clinical validation and medical evidence generation rather than immediate commercial product development.
Hospices Civils de Lyon
Contact us to explore partnerships for the clinical implementation of the SALVOVAR chemotherapy protocols.
